Travere Therapeutics Overview
Travere Therapeutics Target Price
See Travere Therapeutics's analyst price targets ($70) vs the current share price.
Get informed when a big investor buys or sells
+ FollowShare Price
$66.17
Average Target Price
$70.00
5.8% upside
5.8% upside4 analysts in the last 4 months
High: $78 | Low: $65
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-08-10 | Evercore ISI | $78 | 17.9% upside |  |
| 2026-08-06 | Canaccord Genuity | $70 | 5.8% upside | |
| 2026-06-25 | GuggenheimVamil Divan | $65 |  1.8% downside | |
| 2026-06-02 | H.C. WainwrightJoseph Pantginis | $67 | 1.3% upside | |
| 2026-04-14 | Piper Sandler | $49 | 25.9% downside | |
| 2026-04-14 | Guggenheim | $54 | 18.4% downside | |
| 2026-01-14 | GuggenheimVamil Divan | $49 | 25.9% downside | |
| 2025-09-10 | JefferiesMaury Raycroft | $35 | 47.1% downside | |
| 2024-10-31 | Evercore ISILiisa Bayko | $33 | 50.1% downside | |
| 2024-10-21 | Wells FargoMohit Bansal | $27 | 59.2% downside | |
| 2024-10-10 | Evercore ISILiisa Bayko | $30 | 54.7% downside | |
| 2024-10-09 | Bank of America SecuritiesJason Zemansky | $20 | 69.8% downside | |
| 2024-10-01 | BarclaysCarter Gould | $18 | 72.8% downside | |
| 2024-09-27 | GuggenheimVamil Divan | $23 | 65.2% downside | |
| 2024-09-27 | H.C. WainwrightEd Arce | $18 | 72.8% downside | |
| 2024-09-27 | Bank of America SecuritiesGreg Harrison | $18 | 72.8% downside | |
| 2024-09-10 | Canaccord GenuityEd Nash | $23 | 65.2% downside | |
| 2024-09-09 | GuggenheimVamil Divan | $12.5 | 81.1% downside | |
| 2024-08-28 | Piper SandlerNicole Gabreski | $12 | 81.9% downside | |
| 2024-08-02 | H.C. WainwrightEd Arce | $10 | 84.9% downside | |
| 2024-05-07 | Canaccord GenuityEd Nash | $9 | 86.4% downside | |
| 2024-04-24 | H.C. WainwrightEd Arce | $9.5 | 85.6% downside | |
| 2022-12-05 | Wells Fargo | $28 | 57.7% downside | |